13 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp07347 | GA - 2 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 7.70 ± 1.3 µg/mL |
| dbacp07348 | GA - 2 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 70.30 ± 0.9 µg/mL |
| dbacp07349 | GA - 3 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.1 ± 0.7 µg/mL |
| dbacp07350 | GA - 3 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 7.40 ± 0.4 µg/mL |
| dbacp07351 | GA - 4 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.10 ± 0.4 µg/mL |
| dbacp07352 | GA - 4 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 73.0 ± 1.4 µg/mL |
| dbacp07353 | GA - 5 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 5.0 ± 0.3 µg/mL |
| dbacp07354 | GA - 5 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 5.2 ± 0.8 µg/mL |
| dbacp07355 | GA - 7 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 3.70 ± 0.2 µg/mL |
| dbacp07356 | GA - 7 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.0 ± 1.1 µg/mL |
| dbacp07357 | GA - 7 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HepG-2 | Liver Cancer | IC50 = 3.30 ± 0.1 µg/mL |
| dbacp07358 | GA - 8 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | MCF-7 | Breast Cancer | IC50 = 6.90 ± 1.1 µg/mL |
| dbacp07359 | GA - 8 | Structure given in figure | Synthetic (glycyrrhetinic acid (GA)-based peptides) | Apoptosis induction, Bax/p53/caspase activation | MTT assay | HCT-116 | Colon Cancer | IC50 = 60.70 ± 0.6 µg/mL |